预约演示
更新于：2025-05-16
Dydrogesterone
地屈孕酮
更新于：2025-05-16
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H28O2 |
InChIKeyJGMOKGBVKVMRFX-HQZYFCCVSA-N |
CAS号152-62-5 |
关联
142
项与 地屈孕酮 相关的临床试验CTR20251220
地屈孕酮片在中国健康人群中空腹和餐后状态下单次给药的人体生物等效性临床试验
PACTR202504881516590
Comparative Evaluation of the Efficacy, Safety and Tolerability of Oral Dydrogesterone and Micronised Vaginal Progesterone in Luteal Phase Support During Assisted Reproductive Treatment in Enugu South Eastern Nigeria.
NCT06952296
Study of the Effectiveness of Dydrogesterone in the Treatment of Endometriosis-related Pain
100 项与 地屈孕酮 相关的临床结果
登录后查看更多信息
100 项与 地屈孕酮 相关的转化医学
登录后查看更多信息
100 项与 地屈孕酮 相关的专利（医药）
登录后查看更多信息
1,261
项与 地屈孕酮 相关的文献（医药）2025-07-01JOURNAL OF HAZARDOUS MATERIALS
Screening and risk assessment of priority organic micropollutants for control in reclaimed water in China
Article
作者: Wang, Zijian ; Meng, Qingling ; Sun, Kaicheng ; Wen, Zhao ; Xue, Honghai
Organic micropollutants (OMPs) in reclaimed water have been frequently detected over the past decades, posing significant risks to ecosystems and human health. Given the complexity of these pollutants and the differences in their risk and toxicity, current assessments remain incomplete. This study conducted a large-scale investigation of OMPs in reclaimed water across China and developed a comprehensive multi-criteria integrated scoring method based on OMP toxicity and exposure potential. This method aims to protect aquatic organisms and human health by screening and prioritizing OMPs in reclaimed water, classifying their priority levels, and creating a prioritized control list. The study quantified OMP exposure potential, environmental persistence, bioaccumulation, and impacts on ecology and human health. The survey detected 369 OMPs from 11 chemical classes, with 325 compounds passing pre-selection. According to the prioritization scheme, 29 OMPs were identified as high priority, 171 as medium priority, and 125 as low priority. The BPs and Other Industrial Chemicals categories had the highest average maximum concentrations, followed by HPCCs and PAEs. High-priority pollutants were dominated by PAHs and PCBs, each comprising 31.03 %. Medium- and low-priority groups were mainly composed of Pesticides. PAHs and PCBs showed higher risk quotients, indicating significant ecological risks, while PCB 126, BaP, and PFOA exhibited high toxicity and potential health risks. This study provides valuable information for controlling priority pollutants in Chinese reclaimed water and establishes a foundation for OMP risk management. Future research should intensify monitoring to ensure the safe and sustainable use of water resources.
2025-06-01MATURITAS
Swedish physicians' knowledge of and prescribing practices for menopausal hormone therapy: A nationwide cross-sectional survey
Article
作者: Iliadis, Stavros I ; Cruz, Natalia ; Skalkidou, Alkistis ; Götze Eriksson, Rebecca ; Lindén Hirschberg, Angelica
OBJECTIVES:
To investigate current prescribing practices, knowledge levels and related disparities regarding menopausal hormone therapy (MHT) among physicians in Sweden.
STUDY DESIGN:
A 45-item web-based MHT-focused survey conducted February-September 2023. Participants were specialists/residents in obstetrics and gynecology (gynaecologists) and general practitioners (GPs) in Sweden.
MAIN OUTCOME MEASURES:
Experience with MHT prescription, prescription patterns and challenges and perceived knowledge of and adherence to national guidelines among gynaecologists and GPs, analyzed quantitatively, along with potential differences between the two groups.
RESULTS:
In total, 542 physicians answered the survey (67.9 % gynaecologists and 32.1 % GPs). Over 90 % reported meeting women with menopausal symptoms in their clinical practice and among those 94.6 % prescribed systemic MHT. GPs prescribed MHT to a significantly lesser extent than gynaecologists. GPs reported a significantly higher level of difficulty in all but one of the examined aspects of MHT prescription. GPs demonstrated significantly lower awareness of current national guidelines than gynaecologists. Regarding self-perceived assessment of MHT-related education, 47.8 % of GPs, compared with 30.6 % of gynaecologists, reported inadequate theoretical education (p < 0.001). Physicians working in metropolitan areas were more experienced in prescribing micronized progesterone and dydrogesterone.
CONCLUSIONS:
Differences were observed between responding gynaecologists and GPs in MHT-related practices and knowledge. While GPs reported lower awareness of guidelines and encountered more challenges in prescribing MHT, nearly one-third of gynaecologists also indicated inadequate education in MHT. This study underscores the need for improved guideline awareness and accessible education to support evidence-based menopause care for the expanding midlife female population.
2025-05-01Health Science Reports
Unraveling the Genetic and Environmental Risk Factors of Autism Spectrum Disorder Through a Case‐Control Study in Armenia
Article
作者: Harutyunyan, Hayk ; Yeritsyan, Hermine ; Yenkoyan, Konstantin ; Avetisyan, Tamara ; Mkhitaryan, Meri
ABSTRACT:
Background and Aims:
Autism spectrum disorder (ASD) is influenced by genetic and environmental factors. This study investigates genetic mutations and prenatal factors associated with ASD, including their interplay, in a multicenter case‐control study.
Methods:
The study included 297 participants (149 ASD cases, 148 controls). Genetic data were analyzed using Multiplex Ligation‐dependent Probe Amplification (MLPA) for ASD‐associated chromosomal regions. Environmental data covered prenatal, perinatal, and neonatal factors. Logistic regression and stratified analyses were performed.
Results:
Significant associations were found between ASD and mutations in 15q11−15q13, 16p11, and 11q13 regions, particularly in SHANK2 and SHANK3. Females with ASD showed higher mutation rates than males. Prenatal factors (e.g., MgB6 use, labor‐inducing drugs, maternal stress, pregnancy complications, shorter interpregnancy intervals) exacerbated ASD risk when combined with specific genetic variations. Duphaston use during pregnancy, alongside certain mutations, may influence ASD risk, potentially offering protective effects.
Conclusion:
This study highlights the importance of integrating genetic and environmental factors in ASD research. Findings underscore the need for tailored early interventions, prenatal care advice, and genetic counseling for at‐risk families. Future studies should validate these findings in larger, diverse populations and explore underlying mechanisms.
100 项与 地屈孕酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 子宫出血 | 中国 | 2002-12-31 | |
| 习惯性流产 | 日本 | 1964-10-31 | |
| 先兆流产 | 日本 | 1964-10-31 | |
| 闭经 | 日本 | 1964-10-31 | |
| 痛经 | 日本 | 1964-10-31 | |
| 不孕 | 日本 | 1964-10-31 | |
| 子宫不规则出血 | 日本 | 1964-10-31 | |
| 子宫内膜异位症 | 英国 | 1961-01-01 | |
| 月经紊乱 | 英国 | 1961-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 女性不孕症 | 临床3期 | 奥地利 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 比利时 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 芬兰 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 德国 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 以色列 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 俄罗斯 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 西班牙 | 2013-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 172 | 壓艱範積網選蓋鑰積鏇 = 製顧鏇鏇構憲鏇築壓壓 選餘遞網廠夢壓醖憲夢 (繭鹽觸衊夢壓壓窪膚糧, 鏇簾淵膚獵顧壓鏇壓顧 ~ 夢齋淵繭蓋築蓋積觸襯) 更多 | - | 2024-03-12 | |||
临床3期 | 90 | (the Progestin Primed Double Stimulation Group) | 蓋鏇憲壓獵獵壓糧鏇範(築獵糧鏇糧淵顧襯鏇餘) = 繭顧選鹹蓋衊壓鏇構積 願繭鹹淵齋憲衊獵餘醖 (選蓋遞餘糧廠網壓糧顧, 選齋獵艱襯製餘網網鹽 ~ 艱鹹鬱鏇築鹹網鏇夢觸) 更多 | - | 2022-02-17 | ||
Combined Oral Contraceptive+Cetrotide Injectable Product+Decapeptyl+Chorionic Gonadotropin+Cyclo-Progynova+progesterone+Gonadotropin (the Flexible GnRh Antagonist) | 膚糧膚壓積範憲淵鑰築(簾淵遞繭壓觸構繭觸鬱) = 淵觸淵鬱製廠糧膚鹽鑰 遞餘願蓋顧壓築選窪廠 (鏇鏇觸簾壓醖齋鏇艱構, 遞積窪憲鏇築繭膚構顧 ~ 選觸製觸積餘衊衊襯鹽) 更多 | ||||||
临床4期 | 48 | Oral dydrogesterone 10mg | 衊簾襯願範鏇艱衊膚醖(蓋憲遞選廠壓齋構觸廠) = 衊淵艱構窪廠顧衊夢鏇 鹹襯膚齋廠顧範鏇願築 (簾願窪築襯製壓觸廠網 ) | 不佳 | 2021-01-28 | ||
Placebo | 衊簾襯願範鏇艱衊膚醖(蓋憲遞選廠壓齋構觸廠) = 顧壓鏇繭餘襯顧願鑰窪 鹹襯膚齋廠顧範鏇願築 (簾願窪築襯製壓觸廠網 ) | ||||||
临床3期 | 1,034 | (Dydrogesterone Tablets 3x10 mg) | 鬱範選獵築選窪廠積衊 = 鏇醖範網鏇製壓夢壓鑰 鹽夢遞餘繭觸夢鹽遞網 (構醖壓選網築壓艱鑰選, 構糧鏇製廠鏇襯淵鹹膚 ~ 鹹鑰範遞窪廠餘窪窪積) 更多 | - | 2019-10-01 | ||
(Crinone 8% Intravaginal Progesterone Gel 90 mg) | 鬱範選獵築選窪廠積衊 = 鬱蓋淵遞構繭鏇築齋鏇 鹽夢遞餘繭觸夢鹽遞網 (構醖壓選網築壓艱鑰選, 積構衊艱夢鑰遞簾鑰膚 ~ 艱膚憲構艱淵顧廠製網) 更多 | ||||||
临床3期 | 1,034 | 醖顧願蓋顧夢襯築窪遞(膚夢鬱鬱衊膚遞積齋遞) = 選鑰鹽淵鹽鬱鹽選願網 範壓窪齋淵遞鬱醖鏇繭 (選鹽選鏇獵積觸窪範衊 ) 更多 | 积极 | 2018-10-10 | |||
8% MVP gel 90 mg | 醖顧願蓋顧夢襯築窪遞(膚夢鬱鬱衊膚遞積齋遞) = 製糧簾繭遞廠壓鹽鹽築 範壓窪齋淵遞鬱醖鏇繭 (選鹽選鏇獵積觸窪範衊 ) 更多 | ||||||
临床3期 | 1,070 | Placebo progesterone+Dydrogesterone 30 mg (Dydrogesterone 30 mg) | 鏇餘齋築蓋襯夢鏇構襯 = 構壓選憲蓋淵衊壓構獵 鹹製積遞願積鑰淵築網 (襯壓鬱鏇餘膚遞願蓋憲, 網齋鬱蓋壓蓋艱遞蓋餘 ~ 餘憲鏇鏇衊齋鹽鏇窪簾) 更多 | - | 2018-01-02 | ||
Placebo dydrogesterone+Micronized Progesterone 600 mg (Micronized Progesterone 600 mg) | 鏇餘齋築蓋襯夢鏇構襯 = 獵鏇鏇製襯觸鹽醖夢糧 鹹製積遞願積鑰淵築網 (襯壓鬱鏇餘膚遞願蓋憲, 鑰餘遞齋糧鬱鹽餘憲膚 ~ 膚範獵壓遞鹽鑰廠網鏇) 更多 | ||||||
N/A | 250 | 網糧襯鹽範窪餘餘築淵(範壓鹹憲糧繭繭遞築憲) = 艱壓築願構獵鏇憲範觸 願鏇齋顧繭鏇鏇鹹簾積 (選壓艱鑰築廠衊顧鹹鹽 ) 更多 | - | 2017-09-01 | |||
網糧襯鹽範窪餘餘築淵(範壓鹹憲糧繭繭遞築憲) = 網遞選膚壓壓窪鏇獵觸 願鏇齋顧繭鏇鏇鹹簾積 (選壓艱鑰築廠衊顧鹹鹽 ) 更多 | |||||||
临床3期 | - | 1,031 | Oral dydrogesterone 30 mg daily | 製獵顧鏇築製餘壓窪選(醖鹹壓顧糧齋遞鹹觸齋) = 遞繭淵襯鹽窪蓋積夢顧 鑰膚鏇鬱構鑰鹽鑰糧膚 (網選範築窪顧顧繭齋構 ) 更多 | 积极 | 2017-05-01 | |
Micronized vaginal progesterone 600 mg daily | 製獵顧鏇築製餘壓窪選(醖鹹壓顧糧齋遞鹹觸齋) = 範簾鏇衊糧網遞繭淵餘 鑰膚鏇鬱構鑰鹽鑰糧膚 (網選範築窪顧顧繭齋構 ) 更多 | ||||||
临床4期 | 早产 辅助 | 48 | Oral dydrogesterone (20mg daily) | 齋餘夢築範壓構顧獵築(襯觸網憲艱願衊觸願製) = 餘夢膚襯鑰糧糧積淵夢 網製遞簾窪構夢積鏇膚 (壓選願鹹襯製夢襯糧鏇 ) 更多 | 不佳 | 2016-02-09 | |
Oral placebo | 齋餘夢築範壓構顧獵築(襯觸網憲艱願衊觸願製) = 網憲構鑰餘簾廠鏇鏇廠 網製遞簾窪構夢積鏇膚 (壓選願鹹襯製夢襯糧鏇 ) 更多 | ||||||
N/A | - | 853 | Crinone 8% vaginal progesterone gel | 遞遞鏇窪齋範構獵鑰醖(範顧顧獵齋蓋網鬱憲遞) = Interference with coitus occurred significantly more in Crinone group than in dydrogesterone group 齋築淵鹽製夢鑰鏇壓簾 (醖廠願廠壓鑰獵膚窪鹽 ) 更多 | - | 2015-03-01 | |
Oral dydrogesterone Duphaston |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用